UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

The lancet oncology, 2010-09, Vol.11 (9), p.845-852

2010

Volltextzugriff (PDF)

Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status

International journal of molecular sciences, 2023-06, Vol.24 (12), p.10147

2023

Volltextzugriff (PDF)

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study

Clinical and experimental medicine, 2023-12, Vol.23 (8), p.5113-5120

2023

Volltextzugriff (PDF)

Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2002-10, Vol.20 (19), p.4006-4014

2002

Volltextzugriff (PDF)

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

The lancet oncology, 2020-04, Vol.21 (4), p.497-507

2020

Volltextzugriff (PDF)

Immunotherapy‐induced eczema treated with dupilumab

Journal of the European Academy of Dermatology and Venereology, 2024-05, Vol.38 (5), p.e447-e449

2024

Volltextzugriff (PDF)

CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies

British journal of cancer, 2021-09, Vol.125 (6), p.839-845

2021

Volltextzugriff (PDF)

Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials

European journal of cancer (1990), 2023-08, Vol.189, p.112910-112910, Article 112910

2023

Volltextzugriff (PDF)

Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

Annals of surgery, 2009-03, Vol.249 (3), p.420-425

2009

Volltextzugriff (PDF)

Psoriasis caused by pembrolizumab treatment in advanced melanoma: A positive prognostic side effect?

Dermatologic therapy, 2021-09, Vol.34 (5), p.e15050-n/a

2021

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed

Clinical cancer research, 2004-03, Vol.10 (5), p.1657-1663

2004

Volltextzugriff (PDF)

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

JNCI : Journal of the National Cancer Institute, 2011-01, Vol.103 (1), p.21-30

2011

Volltextzugriff (PDF)

Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO

Clinical colorectal cancer, 2022-09, Vol.21 (3), p.220-228

2022

Volltextzugriff (PDF)

Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification—A pooled analysis of TRIBE and TRIBE2 studies by GONO

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.12-12

2020

Volltextzugriff (PDF)

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer

Annals of surgical oncology, 2006-01, Vol.13 (1), p.58-65

2006

Volltextzugriff (PDF)

MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies

Clinical colorectal cancer, 2014-03, Vol.13 (1), p.37-45.e4

2014

Volltextzugriff (PDF)

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status

Critical reviews in oncology/hematology, 2011-06, Vol.78 (3), p.243-251

2011

Volltextzugriff (PDF)

Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono

Annals of oncology, 2013-06, Vol.24, p.iv22-iv22

2013

Volltextzugriff (PDF)

Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen

Clinical colorectal cancer, 2012-03, Vol.11 (1), p.71-76

2012

Volltextzugriff (PDF)

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine

Nature reviews. Clinical oncology, 2009-11, Vol.6 (11), p.670-674

2009

Volltextzugriff (PDF)

Irinotecan in combination with thalidomide in patients with advanced solid tumors : a clinical study with pharmacodynamic and pharmacokinetic evaluation

Cancer chemotherapy and pharmacology, 2006-11, Vol.58 (5), p.585-593

2006

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)
Berichte
(1)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Oncology
(20)
Humans
(19)
Female
(16)
Aged
(14)
Male
(14)
Middle Aged
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Colorectal Neoplasms - Drug Therapy
(11)
Camptothecin - Analogs & Derivatives
(10)
Chemotherapy
(10)
Camptothecin - Administration & Dosage
(9)
Colorectal Neoplasms - Pathology
(9)
Treatment Outcome
(9)
Tumors
(9)
Adult
(8)
Fluorouracil - Administration & Dosage
(8)
Leucovorin - Administration & Dosage
(7)
Metastases
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study

A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients

Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Immunotherapy‐induced eczema treated with dupilumab

CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies

Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials

Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

Psoriasis caused by pembrolizumab treatment in advanced melanoma: A positive prognostic side effect?

A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed

Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest

Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis

Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients

Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO

Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification—A pooled analysis of TRIBE and TRIBE2 studies by GONO

Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer

MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status

Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono

Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine

Irinotecan in combination with thalidomide in patients with advanced solid tumors : a clinical study with pharmacodynamic and pharmacokinetic evaluation

Suchergebnisse filtern